Last reviewed · How we verify
PHENTOLAMINE
PHENTOLAMINE is a drug. It is currently FDA-approved (first approved 1952).
OraVerse accelerates the reversal of soft-tissue anesthesia by causing vasodilation through alpha-adrenergic blockade.
Phentolamine is a small molecule that acts as an adrenergic receptor alpha antagonist. It has been studied in various clinical trials for conditions such as reversal of local anesthesia in children, prostate cancer, diabetes, inflammation, pre-eclampsia complicating pregnancy, and others.
At a glance
| Generic name | PHENTOLAMINE |
|---|---|
| Target | alpha-adrenergic receptors |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1952 |
Mechanism of action
OraVerse contains phentolamine mesylate, which blocks alpha-adrenergic receptors, leading to vasodilation. This increases local blood flow, helping to reverse the effects of local anesthetics like lidocaine with epinephrine.
Approved indications
Common side effects
- injection site pain
- post procedural pain
- headache
Key clinical trials
- Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia (PHASE3)
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE3)
- Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (PHASE3)
- Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity (PHASE1)
- Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences (PHASE4)
- Comparison Between the Use of Phentolamine Versus Glyceryl Trinitrate for Their Effect on Renal Function in Pre-eclampsia Patients in ICU (PHASE4)
- Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances (PHASE3)
- Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHENTOLAMINE CI brief — competitive landscape report
- PHENTOLAMINE updates RSS · CI watch RSS
Frequently asked questions about PHENTOLAMINE
What is PHENTOLAMINE?
How does PHENTOLAMINE work?
When was PHENTOLAMINE approved?
What development phase is PHENTOLAMINE in?
What are the side effects of PHENTOLAMINE?
What does PHENTOLAMINE target?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing